112 related articles for article (PubMed ID: 15483669)
1. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction.
Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669
[TBL] [Abstract][Full Text] [Related]
2. Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine.
Pizzurro GA; Tapia IJ; Sganga L; Podhajcer OL; Mordoh J; Barrio MM
Cancer Immunol Immunother; 2015 Nov; 64(11):1393-406. PubMed ID: 26197849
[TBL] [Abstract][Full Text] [Related]
3. New approaches to the development of adenoviral dendritic cell vaccines in melanoma.
Butterfield LH; Vujanovic L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1399-408. PubMed ID: 21154122
[TBL] [Abstract][Full Text] [Related]
4. The Chemokine Receptor CCR8 Promotes the Migration of Dendritic Cells into the Lymph Node Parenchyma to Initiate the Allergic Immune Response.
Sokol CL; Camire RB; Jones MC; Luster AD
Immunity; 2018 Sep; 49(3):449-463.e6. PubMed ID: 30170811
[TBL] [Abstract][Full Text] [Related]
5. Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion.
Termini JM; Gupta S; Raffa FN; Guirado E; Fischl MA; Niu L; Kanagavelu S; Stone GW
PLoS One; 2017; 12(9):e0184915. PubMed ID: 28910387
[TBL] [Abstract][Full Text] [Related]
6. Inflammasomes within Hyperactive Murine Dendritic Cells Stimulate Long-Lived T Cell-Mediated Anti-tumor Immunity.
Zhivaki D; Borriello F; Chow OA; Doran B; Fleming I; Theisen DJ; Pallis P; Shalek AK; Sokol CL; Zanoni I; Kagan JC
Cell Rep; 2020 Nov; 33(7):108381. PubMed ID: 33207188
[TBL] [Abstract][Full Text] [Related]
7. Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects.
Lesimple T; Moisan A; Carsin A; Ollivier I; Mousseau M; Meunier B; Leberre C; Collet B; Quillien V; Drenou B; Lefeuvre-Plesse C; Chevrant-Breton J; Toujas L
Cancer Immunol Immunother; 2003 Jul; 52(7):438-44. PubMed ID: 12690521
[TBL] [Abstract][Full Text] [Related]
8. Tumour-retained activated CCR7
Lee CYC; Kennedy BC; Richoz N; Dean I; Tuong ZK; Gaspal F; Li Z; Willis C; Hasegawa T; Whiteside SK; Posner DA; Carlesso G; Hammond SA; Dovedi SJ; Roychoudhuri R; Withers DR; Clatworthy MR
Nat Commun; 2024 Jan; 15(1):682. PubMed ID: 38267413
[TBL] [Abstract][Full Text] [Related]
9. Dendritic Cell-Based Immunotherapy: The Importance of Dendritic Cell Migration.
Song MS; Nam JH; Noh KE; Lim DS
J Immunol Res; 2024; 2024():7827246. PubMed ID: 38628676
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: a promising approach for the treatment of prostate cancer.
Sousa-Canavez JM; Canavez FC; Leite KR; Camara-Lopes LH
Genet Vaccines Ther; 2008 Jan; 6():2. PubMed ID: 18205933
[TBL] [Abstract][Full Text] [Related]
11. Cell shape sensing licenses dendritic cells for homeostatic migration to lymph nodes.
Alraies Z; Rivera CA; Delgado MG; Sanséau D; Maurin M; Amadio R; Maria Piperno G; Dunsmore G; Yatim A; Lacerda Mariano L; Kniazeva A; Calmettes V; Sáez PJ; Williart A; Popard H; Gratia M; Lamiable O; Moreau A; Fusilier Z; Crestey L; Albaud B; Legoix P; Dejean AS; Le Dorze AL; Nakano H; Cook DN; Lawrence T; Manel N; Benvenuti F; Ginhoux F; Moreau HD; P F Nader G; Piel M; Lennon-Duménil AM
Nat Immunol; 2024 Jun; ():. PubMed ID: 38834865
[TBL] [Abstract][Full Text] [Related]
12. Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases.
Kurilin V; Alshevskaya A; Sennikov S
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540312
[TBL] [Abstract][Full Text] [Related]
13. Helios as a Potential Biomarker in Systemic Lupus Erythematosus and New Therapies Based on Immunosuppressive Cells.
París-Muñoz A; León-Triana O; Pérez-Martínez A; Barber DF
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203623
[TBL] [Abstract][Full Text] [Related]
14. Unlocking Dendritic Cell-Based Vaccine Efficacy through Genetic Modulation-How Soon Is Now?
Elwakeel A; Bridgewater HE; Bennett J
Genes (Basel); 2023 Nov; 14(12):. PubMed ID: 38136940
[TBL] [Abstract][Full Text] [Related]
15. Exploiting innate immunity for cancer immunotherapy.
Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
[TBL] [Abstract][Full Text] [Related]
16. Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.
Abascal J; Oh MS; Liclican EL; Dubinett SM; Salehi-Rad R; Liu B
Cells; 2023 Oct; 12(19):. PubMed ID: 37830618
[TBL] [Abstract][Full Text] [Related]
17. Targeting innate immune pathways for cancer immunotherapy.
Cao LL; Kagan JC
Immunity; 2023 Oct; 56(10):2206-2217. PubMed ID: 37703879
[TBL] [Abstract][Full Text] [Related]
18. New Insights of CCR7 Signaling in Dendritic Cell Migration and Inflammatory Diseases.
Hong W; Yang B; He Q; Wang J; Weng Q
Front Pharmacol; 2022; 13():841687. PubMed ID: 35281921
[TBL] [Abstract][Full Text] [Related]
19. Epigenetics of Dendritic Cells in Tumor Immunology.
Godoy-Tena G; Ballestar E
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267487
[TBL] [Abstract][Full Text] [Related]
20. Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer.
Brandum EP; Jørgensen AS; Rosenkilde MM; Hjortø GM
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
